Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Grifols SA ADR

GRFS
Current price
7.36 USD +0.12 USD (+1.66%)
Last closed 7.2 USD
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 6 138 331 136 USD
Yield for 12 month -14.52 %
1Y
3Y
5Y
10Y
15Y
GRFS
21.11.2021 - 28.11.2021

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain. Address: Avinguda de la Generalitat, 152, Barcelona, Spain, 08174

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

15.87 USD

P/E ratio

72

Dividend Yield

Current Year

+7 169 657 841 USD

Last Year

+6 595 376 251 USD

Current Quarter

+1 924 621 531 USD

Last Quarter

+1 924 621 531 USD

Current Year

+2 526 248 413 USD

Last Year

+2 427 087 741 USD

Current Quarter

+750 283 601 USD

Last Quarter

+750 283 601 USD

Key Figures GRFS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 1 079 624 960 USD
Operating Margin TTM 14.88 %
PE Ratio 72
Return On Assets TTM 2.3 %
PEG Ratio 0.2628
Return On Equity TTM 3.48 %
Wall Street Target Price 15.87 USD
Revenue TTM 6 656 195 072 USD
Book Value 8.75 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 4.1 %
Dividend Yield
Gross Profit TTM 2 231 530 000 USD
Earnings per share 0.1 USD
Diluted Eps TTM 0.1 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY 178.7 %
Profit Margin 2.84 %

Dividend Analytics GRFS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

65 %

Dividend History GRFS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date 03.06.2021
Forward Annual Dividend Yield
Last Split Factor 2:1
Payout Ratio
Last Split Date 04.01.2016
Dividend Date 14.06.2021

Stock Valuation GRFS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 72
Forward PE 14.881
Enterprise Value Revenue 2.5132
Price Sales TTM 0.8459
Enterprise Value EBITDA 14.016
Price Book MRQ 0.706

Financials GRFS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators GRFS

For 52 weeks

5.3 USD 12.15 USD
50 Day MA 6.78 USD
Shares Short Prior Month 6 709 688
200 Day MA 8.43 USD
Short Ratio 5.47
Shares Short 7 952 371
Short Percent 0.4 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds


S

SX7EEX

14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics